title: Treatment of facial telangiectasias with a diode-pumped Nd:YAG laser at 532 nm.
abstract: OBJECTIVE
  Facial telangiectasias are a common cause of cosmetic concern. Current treatment modalities present various untoward effects and limits. The pulsed dye laser has been considered the gold standard in efficacy and safety; unfortunately it causes postoperative intracutaneous hematomata, discouraging many patients from undergoing this treatment. Several other vascular lasers (argon, tunable dye, copper, krypton, etc.) are disadvantaged by the risk of hypopigmented and atrophic scars.
  
  
  METHODS
  We assessed a recent powerful version of the potassium titanyl phosphate (KTP) 532 nm laser, which delivers sufficient energy in single pulse lasting 10-50 msec (DioLite 532; IRIDEX, Mountain View, CA, USA). Collateral damage is reduced while the heating of the vessel is slow enough to avoid explosive photothermolysis with its associated purpura. Sixty six patients with facial telangiectasias were treated.
  
  
  RESULTS
  In 62/66 patients (93.9%) we achieved a 75-100% clearance of the lesions, while two treatments were needed to reach an acceptable clearance in the remaining 4/66 patients (6.1%). The eventual need for more sessions was well tolerated because the acceptable postoperative appearance allowed patients to continue normal business and social activities between treatments. No permanent complications or undesired effects were noted.
  
  
  CONCLUSIONS
  We conclude that this diode-pumped frequency-doubled Nd:YAG laser is an effective device for the treatment of facial telangiectasias, with a low profile of undesired effects that can be well tolerated by patients.
authors.affiliation: Ospedale S Gerardo di Monza, Italy. danicass@tin.it
authors.forename: D A
authors.initials: DA
authors.lastname: Cassuto
authors.forename: D M
authors.initials: DM
authors.lastname: Ancona
authors.forename: G
authors.initials: G
authors.lastname: Emanuelli
mesh_terms: D000328:Adult; D000368:Aged; D005145:Face; D005260:Female; D006801:Humans; D053685:Laser Therapy; D007834:Lasers / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D013684:Telangiectasis / Q000628:therapy*; D016896:Treatment Outcome